AnaptysBio (NASDAQ:ANAB) Trading 9.1% Higher – Time to Buy?

AnaptysBio, Inc. (NASDAQ:ANAB) shot up 9.1% during trading on Monday . The company traded as high as $17.19 and last traded at $17.01. 261,406 shares changed hands during trading, a decline of 31% from the average session volume of 379,460 shares. The stock had previously closed at $15.59.

Wall Street Analyst Weigh In

A number of research firms have commented on ANAB. HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $52.00 to $19.00 in a research note on Wednesday, December 11th. JPMorgan Chase & Co. reduced their price target on shares of AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Wedbush reissued an “outperform” rating and set a $40.00 price objective (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Truist Financial cut their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday. Finally, BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $44.18.

AnaptysBio Price Performance

The company has a market cap of $466.78 million, a PE ratio of -2.52 and a beta of -0.11. The company has a 50-day moving average of $24.91 and a 200 day moving average of $29.41.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Equities research analysts expect that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Insider Buying and Selling

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 33.70% of the stock is currently owned by company insiders.

Institutional Trading of AnaptysBio

Several institutional investors have recently added to or reduced their stakes in ANAB. Values First Advisors Inc. bought a new stake in shares of AnaptysBio during the third quarter valued at approximately $49,000. nVerses Capital LLC raised its stake in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares in the last quarter. Headlands Technologies LLC raised its stake in shares of AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Point72 DIFC Ltd raised its stake in shares of AnaptysBio by 680.5% during the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 5,342 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.